BioCentury
ARTICLE | Finance

Watching the wave

CStone’s $260M series B to fund PD-L1 trials as Chinese biotech weighs IPO options

May 11, 2018 10:50 PM UTC

After raising the largest ever series B round for a Chinese biotech, CStone Pharmaceuticals Co. Ltd. should have enough funding to run four pivotal cancer studies in parallel as it monitors the performance of the first wave of biotechs to list on the Hong Kong Stock Exchange. The company is considering an IPO in Hong Kong or the U.S. next year, according to SVP and Global Head of Corporate Development Bing Yuan.

CEO Frank Jiang told BioCentury, “A handful of Chinese biotechs will be among the first wave to be listed in Hong Kong, and their performance in the market will be a very critical factor for us when deciding where to list.” ...

BCIQ Company Profiles

CStone Pharmaceuticals Co. Ltd.